Prospectus

Praxis Precision Medicines Prices Public Offering of Common Stock

Initial public offering, Financial economics, Finance, Corporate finance, Money, Public offering, Prospectus, Praxis, Offering, Stock market
Friday, May 14, 2021 - 3:39am

b'CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.25 per share.

Key Points: 
  • b'CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.25 per share.
  • The gross proceeds to Praxis from the offering are expected to be approximately $91.25 million, before deducting the underwriting discounts and commissions and other offering expenses.
  • Praxis has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock.\nAll shares in the offering are to be sold by Praxis.
  • The public offering is being made by Praxis only by means of a prospectus relating to the offering.

Monaker Group Announces Pricing of $8.1 Million Underwritten Public Offering of Common Stock

Initial public offering, Prospectus, Forward-looking statement, Stock market, SEC filings, Red herring prospectus
Friday, May 14, 2021 - 1:54am

333-224309) that became effective with the Securities and Exchange Commission (SEC) on July 2, 2018, the base prospectus contained therein and the accompanying prospectus supplement.

Key Points: 
  • 333-224309) that became effective with the Securities and Exchange Commission (SEC) on July 2, 2018, the base prospectus contained therein and the accompanying prospectus supplement.
  • A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering has been filed with the SEC.
  • Monaker Group is a party to a definitive agreement (subject to closing conditions) to acquire HotPlay Enterprise Limited, an innovative in-game advertising and AdTech company.
  • If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.\n'

Vera Therapeutics Announces Pricing of Initial Public Offering

Initial public offering, Financial economics, Finance, Financial markets, Public offering, Registration statement, Prospectus
Friday, May 14, 2021 - 1:52am

b'SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (\xe2\x80\x9cVera\xe2\x80\x9d), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the pricing of its initial public offering of 4,350,000 shares of its Class A common stock at a price to the public of $11.00 per share.

Key Points: 
  • b'SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (\xe2\x80\x9cVera\xe2\x80\x9d), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the pricing of its initial public offering of 4,350,000 shares of its Class A common stock at a price to the public of $11.00 per share.
  • The gross proceeds to Vera from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $47.85 million.
  • All of the shares are being offered by Vera.
  • This offering is being made only by means of a written prospectus, forming a part of the effective registration statement.

SAVE FOODS, INC. ANNOUNCES PRICING OF $12 MILLION PUBLIC OFFERING AND NASDAQ LISTING

Initial public offering, Finance, Financial economics, Money, Prospectus, Public offering, Underwriting, Red herring prospectus
Thursday, May 13, 2021 - 10:50pm

Save Foods has granted the underwriter a 45-day option to purchase up to 163,636 additional shares of Common Stock to cover over-allotments, if any, at the public offering price, less the underwriting discounts and commissions.

Key Points: 
  • Save Foods has granted the underwriter a 45-day option to purchase up to 163,636 additional shares of Common Stock to cover over-allotments, if any, at the public offering price, less the underwriting discounts and commissions.
  • The Offering is expected to close May 18, 2021, subject to satisfaction of customary closing conditions.
  • A final prospectus relating to this offering will be filed with the Securities and Exchange Commission.
  • Because such statements deal with future events and are based on Save Foods\xe2\x80\x99 current expectations, they are subject to various risks and uncertainties.

Eloxx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Finance, Financial economics, Financial markets, Initial public offering, Corporate finance, Stock market, Public offering, Prospectus, NASDAQ, Stock
Thursday, May 13, 2021 - 9:01pm

b"WALTHAM, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the \xe2\x80\x9cCompany\xe2\x80\x9d) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock.

Key Points: 
  • b"WALTHAM, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the \xe2\x80\x9cCompany\xe2\x80\x9d) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock.
  • In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock at the public offering price, less underwriting discounts and commissions.\nB.
  • Riley Securities, Inc. is acting as sole-book running manager for the offering.
  • The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

Monaker Group Announces Proposed Public Offering of Common Stock

Initial public offering, Finance, Financial economics, Money, Corporate finance, Financial markets, Prospectus, Public offering, NASDAQ, Stock market
Thursday, May 13, 2021 - 9:05pm

b'Sunrise, FL, May 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Monaker Group, Inc. (NASDAQ: MKGI), a technology solutions company focused on building a digital business ecosystem that caters to and ties together digital advertisers, consumers, video gamers and travelers, today announced that it has commenced an underwritten public offering of its common stock.

Key Points: 
  • b'Sunrise, FL, May 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Monaker Group, Inc. (NASDAQ: MKGI), a technology solutions company focused on building a digital business ecosystem that caters to and ties together digital advertisers, consumers, video gamers and travelers, today announced that it has commenced an underwritten public offering of its common stock.
  • All of the shares in the offering are being offered by Monaker.
  • In addition, Monaker expects to grant the underwriters a 45-day option to purchase up to an additional 15% of shares of its common stock on the same terms and conditions.
  • A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering has been filed with the SEC.

Rover to Participate in the Needham Technology & Media Conference on May 18 and the Stifel Cross Sector Insight Conference on June 10

SEC filings, Shareholders, Proxy statement, Statements, Prospectus, Rover, Proxy, Corporations
Thursday, May 13, 2021 - 9:05pm

Rover connects dog and cat owners with pet care whenever they need it.

Key Points: 
  • Rover connects dog and cat owners with pet care whenever they need it.
  • To learn more about Rover, please visit http://www.rover.com .\nTrue Wind Capital is a San Francisco-based private equity firm focused on investing in leading technology companies.
  • A definitive proxy statement/prospectus/information statement will also be sent to the stockholders of Caravel and Rover, seeking any required stockholder approvals.
  • The documents filed by Caravel with the SEC may be obtained free of charge at the SEC\xe2\x80\x99s website at www.sec.gov.

Greenbrook TMS Provides Update on Public Offering

Biotechnology, General Health, Mental health, Medical devices, Health, U.S. Securities and Exchange Commission, Initial public offering, Prospectus, Registration statement
Thursday, May 13, 2021 - 10:05pm

The Company expects to amend the Prospectus and the Registration Statement prior to the Offering.

Key Points: 
  • The Company expects to amend the Prospectus and the Registration Statement prior to the Offering.
  • Prospective Canadian investors should clearly indicate in their request that they are a Canadian prospective investor and are requesting a copy of the Canadian Prospectus.
  • TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation.
  • In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information.

McGrath RentCorp to Acquire Design Space Modular Buildings

Commercial Building & Real Estate, Construction & Property, Transport, Other Transport, Communication, Forward-looking statement, Prospectus, Financial statements, Auditing, Accounting, SEC filings, Business, Economy
Thursday, May 13, 2021 - 9:01pm

Forward-looking statements involve significant risks and uncertainties that may cause actual results to differ materially from such forward-looking statements.

Key Points: 
  • Forward-looking statements involve significant risks and uncertainties that may cause actual results to differ materially from such forward-looking statements.
  • These statements are based on current plans, estimates and projections, and, therefore, you should not place undue reliance on them.
  • No forward-looking statement, including any such statement concerning the completion and anticipated benefits of the proposed transaction, can be guaranteed, and actual results may differ materially from those projected.
  • Any such offer will only be made by means of a prospectus or offering memorandum, and in compliance with applicable securities laws.

Stable Road Stockholders Approve Extension of the Date to Consummate Proposed Business Combination with Momentus

Finance, Consulting, Banking, Professional services, Other Professional Services, SEC filings, Shareholders, Proxy statement, Statements, U.S. Securities and Exchange Commission, Prospectus, Corporate finance, Registration statement, Stock market, Financial markets
Thursday, May 13, 2021 - 5:37pm

With an experienced team of aerospace, propulsion, and robotics engineers, Momentus has developed a cost-effective and energy efficient in-space transport system based on water plasma propulsion technology.

Key Points: 
  • With an experienced team of aerospace, propulsion, and robotics engineers, Momentus has developed a cost-effective and energy efficient in-space transport system based on water plasma propulsion technology.
  • Momentus has in-place service agreements with private satellite companies and research organizations.\nIn connection with the proposed transaction contemplated by the merger agreement between Stable Road and Momentus (the \xe2\x80\x9cProposed Transaction\xe2\x80\x9d), Stable Road has filed with the SEC a registration statement on Form S-4 (the \xe2\x80\x9cRegistration Statement\xe2\x80\x9d) that includes a proxy statement of Stable Road, a consent solicitation statement of Momentus and prospectus of Stable Road, and each party will file other documents with the SEC regarding the Proposed Transaction.
  • The Registration Statement has not been declared effective by the SEC.
  • When available, the definitive proxy statement/consent solicitation statement/prospectus will be mailed to Stable Road\xe2\x80\x99s stockholders as of a record date to be established for voting on the Proposed Transaction and the other matters to be voted upon at the Proposed Transaction Special Meeting.